In Brief: DVI Atherocath-GTO
This article was originally published in The Gray Sheet
Executive SummaryDVI Atherocath-GTO: Devices for Vascular Intervention resumes shipment of the atherectomy catheter after receiving approval of a PMA supplement for modifications made to the device. The Guidant unit halted shipments of the GTO on May 17 after it was notified by FDA that approval of the changes was required. The company says it will continue to ship the AtheroCath SCA-EX, an earlier version atherectomy catheter that was being sold in place of the GTO...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.